80
Participants
Start Date
October 18, 2018
Primary Completion Date
August 10, 2021
Study Completion Date
August 10, 2021
FPT155
A soluble CD80 fusion protein
pembrolizumab
An anti-PD1 antibody
St Vincent's Hospital Sydney, Darlinghurst
Scientia Clinical Research, Randwick
Chris O'Brien Lifehouse, Camperdown
Olivia Newton-John Cancer Center, Heidelberg
Cabrini Hospital, Malvern
ICON, Auchenflower
Linear Clinical Research, Nedlands
National Cancer Center, Goyang-si
St Vincent Hospital of the Catholic University of Korea, Suwon
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
Lead Sponsor
Five Prime Therapeutics, Inc.
INDUSTRY